In one paragraphReview in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Benoit AguadoUniversité Paris-Saclay, INSERM UMR_S 1358, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Hôpital Bicêtre (AP-HP), Hôpital Marie Lannelongue, FHU André Cournand, ERN-LUNG, Le Plessis Robinson, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0009-0005-6895-194X Thomas Lacoste-PalassetUniversité Paris-Saclay, INSERM UMR_S 1358, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Hôpital Bicêtre (AP-HP), Hôpital Marie Lannelongue, FHU André Cournand, ERN-LUNG, Le Plessis Robinson, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0003-3543-6675 Grégoire RuffenachUniversité Paris-Saclay, INSERM UMR_S 1358, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Hôpital Bicêtre (AP-HP), Hôpital Marie Lannelongue, FHU André Cournand, ERN-LUNG, Le Plessis Robinson, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0001-6419-4332 Fabrice BauerUniversité Paris-Saclay, INSERM UMR_S 1358, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Hôpital Bicêtre (AP-HP), Hôpital Marie Lannelongue, FHU André Cournand, ERN-LUNG, Le Plessis Robinson, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-9221-9688 Laurent SavaleUniversité Paris-Saclay, INSERM UMR_S 1358, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Hôpital Bicêtre (AP-HP), Hôpital Marie Lannelongue, FHU André Cournand, ERN-LUNG, Le Plessis Robinson, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-6862-8975 Marc HumbertUniversité Paris-Saclay, INSERM UMR_S 1358, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Hôpital Bicêtre (AP-HP), Hôpital Marie Lannelongue, FHU André Cournand, ERN-LUNG, Le Plessis Robinson, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0003-0703-2892 David MontaniUniversité Paris-Saclay, INSERM UMR_S 1358, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Hôpital Bicêtre (AP-HP), Hôpital Marie Lannelongue, FHU André Cournand, ERN-LUNG, Le Plessis Robinson, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-9358-6922 Fabrice AntignyUniversité Paris-Saclay, INSERM UMR_S 1358, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique (HPPIT), Hôpital Bicêtre (AP-HP), Hôpital Marie Lannelongue, FHU André Cournand, ERN-LUNG, Le Plessis Robinson, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-9515-6571 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Pulmonary hypertension (PH) is a progressive and multifactorial disease marked by elevated pulmonary arterial pressure and right ventricular (RV) dysfunction. Among its subtypes, pulmonary arterial hypertension (PAH) is characterised by profound vascular remodelling, inflammation and fibrosis. Despite therapeutic advances targeting the endothelin, nitric oxide, prostacyclin, and, more recently, the activin signalling pathway
Identifiers
PMID42232566
PMCPMC13224206
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390